Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The RESTORE trial: What did we learn about multiple sclerosis?
Role of serum TRAIL level and TRAIL apoptosis gene expression in multiple sclerosis and relation to brain atrophy.
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Potential therapeutic benefit of c1-esterase inhibitor in neuromyelitis optica evaluated in vitro and in an experimental rat model.
Vitamin D in allergic disorders.
White Matter MS-Lesion Segmentation Using a Geometric Brain Model.
Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators.
Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases.
NDRG2 promoted secreted miR-375 in microvesicles shed from M1 microglia, which induced neuron damage.
Plasmablast in the pathology of multiple sclerosis.
Core muscle strength and endurance measures in ambulatory persons with multiple sclerosis: validity and reliability.
[Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
Differentiation and quantification of inflammation, demyelination and axon injury or loss in multiple sclerosis.
Intracortical Posterior Cingulate Myelin Content Relates to Error Processing: Results from T1- and T2-Weighted MRI Myelin Mapping and Electrophysiology in Healthy Adults.
The therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
[Alemtuzumab for relapsing-remitting multiple sclerosis : Results of two randomized controlled phase III studies.]
Plasma levels of neuron specific enolase quantify the extent of neuronal injury in murine models of ischemic stroke and multiple sclerosis.
IL2RA Allele Increases Risk of Neuromyelitis Optica in Southern Han Chinese.
Ultrasonographic diagnosis of demyelinating neuropathy.
Olfactory memory impairment in neurodegenerative diseases.
Phonological fluency strategy of switching differentiates relapsing-remitting and secondary progressive multiple sclerosis patients.
Effects of pregnancy and breastfeeding on the multiple sclerosis disease course.
Subsequent brain tumors in patients with autoimmune disease.
Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine.
Pages
« first
‹ previous
…
463
464
465
466
467
468
469
470
471
…
next ›
last »